Biotech

All Articles

Alnylam abandons clinical-stage Kind 2 diabetes mellitus property

.Alnylam is actually putting on hold even further progression of a clinical-stage RNAi curative deve...

Takeda ceases period 2 sleep apnea test over sluggish enrollment

.Takeda has actually quit (PDF) a phase 2 trial of danavorexton because of sluggish enrollment, noti...

Compass problems stage 3 experimental data, lays off 30% of workers

.Compass Pathways' journey to period 3 psychedelic anxiety information is taking much longer than an...

Former Seagen CEO reveals brand-new startup Ottimo Pharma

.After antibody-drug conjugate (ADC) professional Seagen was sold to Pfizer last year for a massive ...

Ironwood makes additional bid for $1B GI medication along with new subgroup information

.On the heels of a stage 3 win that neglected to thrill financiers, Ironwood Pharmaceuticals is back...

Novartis inks $150M bargain for autoimmune molecular glue

.Don't quit Monte Rosa Therapeutics currently. The Boston-based biotech is having a ball after signi...

Jade carves out officer staff with Chinook vets-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of notable leadership hirings, firings and a...

Septerna goes public along with upsized offering of $288M

.Celebrating his business's upsized going public (IPO), Septerna chief executive officer Jeffrey Fin...

AbbVie creates Richter richer, paying $25M to create invention contract

.AbbVie has gone back to the source of its antipsychotic powerhouse Vraylar seeking one more smash h...

GenSight gets in ultimate full weeks of cash money path as earnings flow slips by of grasp

.GenSight Biologics is full weeks off of losing loan. Once more. The biotech merely has enough cash ...